Radiological monitoring of the treatment of solid tumors in practice

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 186, Issue 5, 2014, Pages 466-473

  Ganten, M K ^a   Ganten, T M ^b   Schlemmer, H P ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

CT; metastases; staging

Indexed keywords

CANCER PATIENT; CANCER THERAPY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG MECHANISM; FOLLOW UP; GLIOMA; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84899472528     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0033-1356329     Document Type: Review

References (38)

1. Nennecke A., Brenner H., Eberle A. et al. Überlebenschancen von Krebspatienten in Deutschland: auf dem Weg zu repräsentativen, vergleichbaren Aussagen. Gesundheitswesen: 2010; 72 692 699
2. Galbraith S. M. MR in oncology drug development. NMR in biomedicine: 2006; 19 681 689
3. Milano A., Perri F., Ciarmiello A. et al. Targeted-therapy and imaging response: a new paradigm for clinical evaluation? Rev Recent Clin Trials: 2011; 6 259 265
4. Romero-Camarero I., Barajas-Diego M., Castellanos-Martin A. et al. New models towards assessing anti-cancer therapeutics. Histology and histopathology: 2012; 27 157 170
5. Siegmund-Schultze N. Onkologie: Erfolge bei metastasierten Tumoren. Dtsch Arztebl: 2012; 109 27 28
6. Cousin S., Taieb S., Penel N. A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials. Current opinion in oncology: 2012; 24 338 344
7. Choi H. Response evaluation of gastrointestinal stromal tumors. The oncologist: 2008; 13 4 7
8. Lencioni R., Llovet J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease: 2010; 30 52 60
9. Wolchok J. D., Hoos A., O'Day S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical cancer research: an official journal of the American Association for Cancer Research: 2009; 15 7412 7420
10. Abou-Alfa G. K., Schwartz L., Ricci S. et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol: 2006; 24 4293 4300
11. Ganten M. K., Weber M. A., Ganten T. M. Zelluläre Mechanismen der Tumorresponse, klinische Anforderungen. Radiologe: 2008; 48 820 831
12. Herzer K., Ganten T. M., Schulze-Bergkamen H. et al. Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology: 2005; 42 183 192
13. Miller A. B., Hoogstraten B., Staquet M. et al. Reporting results of cancer treatment. Cancer: 1981; 47 207 214
14. Wen P. Y., Macdonald D. R., Reardon D. A. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol: 2010; 28 1963 1972
15. Therasse P., Arbuck S. G., Eisenhauer E. A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst: 2000; 92 205 216
16. Eisenhauer E. A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer: 2009; 45 228 247
17. Schwartz L. H., Bogaerts J., Ford R. et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer: 2009; 45 261 267
18. Tsuchida Y., Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Medical and pediatric oncology: 2001; 37 1 3
19. Gebauer B., Bohnsack O., Riess H. Radiologische Evaluation des Tumoransprechens in onkologischen Therapiestudien (Tumor Response Evaluation). Fortschr Röntgenstr: 2011; 183 695 703
20. Karul M. RECIST ist einfach-mit RECIST zu arbeiten jedoch nicht! Radiologe: 2011; 51 653
21. Wulff A. M., Bolte H., Fischer S. et al. Lung, liver and lymph node metastases in follow-up MSCT: comprehensive volumetric assessment of lesion size changes. Fortschr Röntgenstr: 2012; 184 820 828
22. Levine Z. H., Pintar A. L., Hagedorn J. G. et al. Uncertainties in RECIST as a measure of volume for lung nodules and liver tumors. Medical physics: 2012; 39 2628 2637
23. Buchmann I., Ganten T. M., Haberkorn U. FDG-PET in der Diagnostik gastrointestinaler Tumoren. Zeitschrift fur Gastroenterologie: 2008; 46 367 375
24. Wahl R. L., Jacene H., Kasamon Y. et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. Journal of nuclear medicine: official publication, Society of Nuclear Medicine: 2009; 50 122S 150S
25. Ganten M. K. Verlaufsbeurteilung des malignen Lymphoms. Radiologe: 2012; 52 330 337
26. Cheson B. D., Pfistner B., Juweid M. E. et al. Revised response criteria for malignant lymphoma. J Clin Oncol: 2007; 25 579 586
27. Cheson B. D., Horning S. J., Coiffier B. et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol: 1999; 17 1244
28. Wessling J., Puesken M., Koch R. et al. MSCT follow-up in malignant lymphoma: comparison of manual linear measurements with semi-automated lymph node analysis for therapy response classification. Fortschr Röntgenstr 184 795 804
29. Rimassa L., Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert review of anticancer therapy: 2009; 9 739 745
30. Kalkmann J., Zeile M., Antoch G. et al. Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging: 2012; 12 126 135
31. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell: 2000; 100 57 70
32. Padhani A. R., Koh D. M., Collins D. J. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology: 2011; 261 700 718
33. Padhani A. R., Miles K. A. Multiparametric imaging of tumor response to therapy. Radiology: 2010; 256 348 364
34. Fueger B. J., Helbich T. H., Schernthaner M. et al. Stellenwert der multiparametrischen Magnetresonanztomographie beim Prostatakarzinom. Radiologe: 2011; 51 947 954
35. Padhani A. R. Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging: 2011; 11 S27 S37
36. Li S. P., Padhani A. R. Tumor response assessments with diffusion and perfusion MRI. Journal of magnetic resonance imaging: JMRI: 2012; 35 745 763
37. Mangold S., Thomas C., Fenchel M. et al. Virtual Nonenhanced Dual-Energy CT Urography with Tin-Filter Technology: Determinants of Detection of Urinary Calculi in the Renal Collecting System. Radiology: 2012; 264 119 125
38. Ratain M. J., Eckhardt S. G. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol: 2004; 22 4442 4445